Fundz

C-Gen.AI raises $3.5 million in seed funding to enhance AI infrastructure and GPU utilization, emerging from stealth to revolutionize AI workloads.

PUBLIC · CGENJul 15, 2025

Amount Raised

$3.5 Million

Round Type

Seed

Tel AvivOtherBiotechnologyHealth CareMedicalTherapeuticsBiotechnology Research

Description

C-Gen.AI has announced a $3.5 million seed funding to develop its innovative GPU orchestration platform. This funding will support the company's mission to resolve inefficiencies in AI infrastructure. Founded by Sami Kama, C-Gen.AI aims to enhance deployment capabilities for startups and enterprises. The funding, provided by key players in the infrastructure and AI sectors, will facilitate the scaling of their groundbreaking technology.

Quick answer

Compugen raised $3.5 Million in a Seed round, dated July 15, 2025. Compugen is based in Tel Aviv, Tel Aviv District, Israel.

How much did Compugen raise?
Compugen raised $3.5 Million in a Seed round on July 15, 2025.
What does Compugen do?
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for..
Where is Compugen based and how big is it?
Compugen is based in Tel Aviv, Tel Aviv District, Israel.
Who are the decision-makers at Compugen?
Fundz holds 1 contact at Compugen. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as Compugen that raised within 45 days of this round, from Fundz verified event records.

  • Immuneering raised $25M on August 26, 2025.
  • Faeth Therapeutics raised $24M on August 1, 2025.
  • BioSapien raised $8M (Pre-Series A) on July 7, 2025.
  • FELIQS raised $9M (Series A) on July 1, 2025.
  • PainTEQ raised an undisclosed amount (Funding Round) on August 27, 2025.
  • Moonrise Medical raised $396K on August 27, 2025.

Who to call at Compugen, and when

A new round usually means Compugen is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Compugen raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Compugen, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Compugen. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Compugen

Location

26 HAROKMIM STREET

Tel Aviv, Tel Aviv District, Israel

About

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Compugen raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts13 people are listed at Compugen. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Compugen's next move

See what Strategic adds

Compugen raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.